Background:The Ten-Eleven Translocation 1 gene (TET1) is a member of the TET methyl cytosine dioxygenase family of enzymes (TET1, TET2, and TET3). The TET1 has contrasting roles in myeloid and lymphoid transformation being either an oncogene or a tumor suppressor. This work aimed to study the expression level of TET1 gene in acute leukemia patients and its correlation with clinical and pathological criteria of these patients. Patients & methods:This study was conducted on 73 acute leukemia patients. Bone marrow samples were analyzed using Real Time PCR 7500s.Results:There was significant correlation between expression levels of TET 1 gene in acute leukemia patients and their clinical and pathological criteria.Conclusion:It has been found that expression levels of TET1 gene in patients’ samples were higher in in AML, not otherwise specified (NOS), and T lymphoblastic leukemia/lymphoma patients and lower in B lymphoblastic leukemia/lymphoma, NOS patients. Besides, this study showed the significant relation between TET1 gene and the percentage of blast cells in peripheral blood (P.B) and bone marrow (B.M) and generalized lymphadenopathy. These findings revealed the great role of TET1 gene dysregulation in leukemogenesis; also its possible usage as a potential target for treating this form of hematopoietic malignancy.

Background:The Ten-Eleven Translocation 1 gene (TET1) is a member of the TET methyl cytosine dioxygenase family of enzymes (TET1, TET2, and TET3). The TET1 has contrasting roles in myeloid and lymphoid transformation being either an oncogene or a tumor suppressor. This work aimed to study the expression level of TET1 gene in acute leukemia patients and its correlation with the clinical and pathological criteria of these patients. Patients & methods:This study was conducted on 73 acute leukemia patients. Bone marrow samples were analyzed using Real-Time PCR 7500s.Results:There was a significant correlation between expression levels of TET 1 gene in acute leukemia patients and their clinical and pathological criteria.Conclusion:It has been found that expression levels of TET1 gene in patients’ samples were higher in AML, not otherwise specified (NOS), and T lymphoblastic leukemia/lymphoma patients and lower in B lymphoblastic leukemia/lymphoma, NOS patients. Besides, this study showed the significant relation between TET1 gene and the percentage of blast cells in peripheral blood (P.B) and bone marrow (B.M) and generalized lymphadenopathy. These findings revealed the great role of TET1 gene dysregulation in leukemogenesis; also its possible usage as a potential target for treating this form of hematopoietic malignancy.